Close X
 
 

Insulin past, present and future


New content
 
 

In a lively and thought-provoking contribution to our Insulin@100 series, Professor Tina Vilsbøll takes us on a whistlestop tour of insulin’s clinical use – past, present and future.

 
 
 
 

Professor Vilsbøll, who is a Professor at the University of Copenhagen and a consultant at the Steno Diabetes Centre, is known for her work as a researcher in the field of GLP-1. Her focus in this presentation is chiefly on the changing role of insulin in the management of type 2 diabetes. “When I was a young PhD student, insulin was seen almost as a threat by type 2 patients because they were told that if metformin and sulphonylureas were not enough then eventually they would go onto insulin injections. And they were really worried - about gaining weight, hypoglycaemia and a host of other things.”

 
 
 
 

This prospect has been transformed, she explains - partly because of improvements in the insulins now available. But also because of the advent of other glucose-lowering drugs - including GLP-1 receptor agonists and SGLT-2 inhibitors. “They really changed what it meant to be a diabetologist today and, indeed, a patient with type 2 diabetes.”

 
 
 
 

“It has been an interesting story so far,” she concludes, “but I must say that I'm so much looking forward to the future.”

 
 
 
 

But the journey isn’t over yet, Professor Vilsbøll insists. “Here at Steno we initiated a trial comparing once-daily insulin with once-weekly insulin, so that’s the future.” Also in the pipeline are glucose-level dependent insulins, which only work when blood glucose is high. And fixed-ratio combinations, which combine insulin and GLP-1 receptor agonists in one pen.

 
 
 
 

“It has been an interesting story so far,” she concludes, “but I must say that I'm so much looking forward to the future.”

 
 
 
 

Click here to watch Professor Vilsbøll’s presentation, ‘An interesting journey’.

 
 
 
 

For more on GLP-1 receptor agonists, see our course – including Professor Vilsbøll’s two modules ‘GLP-1 and cardiovascular disease’ and ‘GLP-1 and obesity, NAFLD and NASH’.

 
WP_Post Object ( [ID] => 26892 [post_author] => 4 [post_date] => 2021-03-01 10:12:15 [post_date_gmt] => 2021-03-01 10:12:15 [post_content] => [post_title] => Metabolic surgery [post_excerpt] => [post_status] => private [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => metabolic-surgery [to_ping] => [pinged] => [post_modified] => 2021-05-10 16:23:42 [post_modified_gmt] => 2021-05-10 15:23:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://easd-elearning.org/?post_type=sfwd-courses&p=26892 [menu_order] => 0 [post_type] => sfwd-courses [post_mime_type] => [comment_count] => 0 [filter] => raw )
Launching soon
Metabolic surgery
Other recent news